T.Man Pharmaceutical Valuation
Is TMAN-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TMAN-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TMAN-R (THB16.9) is trading above our estimate of fair value (THB7.36)
Significantly Below Fair Value: TMAN-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TMAN-R?
Other financial metrics that can be useful for relative valuation.
What is TMAN-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿6.76b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.2x |
Enterprise Value/EBITDA | 11.5x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does TMAN-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 25.5x | ||
BLC Bangkok Lab And Cosmetic | 19.3x | n/a | ฿3.1b |
MEGA Mega Lifesciences | 16.7x | 11.7% | ฿33.3b |
JSP JSP Pharmaceutical Manufacturing (Thailand) Public | 44.1x | n/a | ฿968.1m |
AFT AFT Pharmaceuticals | 22x | 26.7% | NZ$344.0m |
TMAN-R T.Man Pharmaceutical | 16.1x | n/a | ฿6.8b |
Price-To-Earnings vs Peers: TMAN-R is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (25.5x).
Price to Earnings Ratio vs Industry
How does TMAN-R's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: TMAN-R is good value based on its Price-To-Earnings Ratio (16.1x) compared to the Asian Pharmaceuticals industry average (25.8x).
Price to Earnings Ratio vs Fair Ratio
What is TMAN-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 16.1x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMAN-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.